Transformational Science that Transforms Lives
Immunocore is a leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform. The scientific expertise at Immunocore spans the entire process of drug development. From the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, and preclinical and clinical assessment.
Sep 05, 2018 Immunocore strengthens IP position in the field of TCR-based therapeutics
Aug 20, 2018 Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
Jul 16, 2018 Immunocore Announces Management Change
